The Impact of PPAR𝜸 Genetic Variants on IBD Susceptibility and IBD Disease Course

Table 1

Demographic characteristics of IBD patients and non-IBD controls.

Patient cohort
	UC	CD	IBD total
N (%) of patients	140 (49.3)	144 (50.7)	284 (100)
Male/female N (%)	77 (54.6)/64 (45.4)	77 (55)/63 (45)	140 (49.3)/144 (50.7)
Age at enrolment	44.02±14.69	38.59±14.95	41.27±15.04
Disease location N (%)	Available for 110 UC patients:	Available for 125 CD patients (Montreal classification)
	E1: 11 (10%)	L1: 33 (26.4%)
	E2: 58 (52.7%)	L2: 42 (33.6%)
	E3: 41 (37.3%)	L3: 46 (36.8%)
		L4: 4 (3.2%)
EIM frequency N (%)	Available for 139 UC patients:	Available for 142 CD patients:	Available for 281 IBD patients:
	51 (36.7)	72 (50.7)	123 (43.8)
Fistula frequency N (%)	Available for 140 UC patients:	Available for 144 CD patients:	Available for 284 IBD patients:
	10 (7.1)	73 (50.7)	83 (29.2)
Mean CDAI at enrolment	NA	Available for 127 CD patients: 110.56±75.81	NA
State of CD (quiescent/acute) N (%)	NA	Available for 127 CD pat.:	NA
		95 (74.8)/32 (25.2)
Mean mtwsi at enrolment	Available for 140 UC patients: 4.69±4.31	NA	NA
State of UC (inactive/active) N (%)	118 (84.3)/22 (15.7)	NA	NA
Leucocytes at enrolment	Valid for 134 UC patients: 17.45±79.29	Available for 142 CD patients: 8.9±7.85	Available for 276 IBD patients: 13.05±55.59
CRP at enrolment	Valid for 127 CD patients: 9.58±15.31	Available for 138 CD patients: 12.23±22.64	Available for 265 IBD patients: 10.96±19.48
Control cohort
			Control total
N of controls (%)			194 (100)
Male/female N (%)			77 (39.7)/117 (60.3)
Age at enrolment			41.01±16.5

N: absolute number; E1: rectal UC; E2: left-sided UC; E3: extensive UC; L1: ileal CD; L2: colonic CD; L3: ileocolonic CD; L4: CD of upper GI; EIMs: extraintestinal manifestations; CDAI: Crohn’s activity index; mtwsi: modified Truelove Witts severity index.